CluePoints, a Louvain-La-Neuve, Belgium-based provider of a cloud-based software platform for Risk-Based Quality Management (“RBQM”) and data quality oversight in clinical trials, received a majority investment from EQT.
The amount of the deal was not disclosed. The transaction is subject to customary conditions and approvals. It is expected to close in Q3 2024. Summit Partners, an investor in CluePoints since 2020, and Clinimetrics SA, a co-founder of CluePoints, will retain minority stakes with participation in this funding round.
The company intends to use the funds to expand operations and its business reach.
Led by CEO Andy Cooper, CluePoints is a premier software provider for RBQM and data quality oversight in clinical trials. Applying advanced statistics and machine learning, and harnessing over 10 years of clinical trials knowledge, CluePoints’ proprietary algorithms help drive positive outcomes for pharmaceutical and biotech companies, contract research organizations and other customers. The company offers an end-to-end value proposition from initial risk identification to ongoing tracking and monitoring of issues and discrepancies throughout the drug development process. With more than 9,500 platform users, CluePoints has helped de-risk more than 1,600 studies and has detected over 142,000 issues for its customers, which include many of the top 20 largest pharma companies.
FinSMEs
12/06/2024